Mergers & Acquisitions ·
Theravance Biopharma shareholders approved the proposed merger with Zymeworks Inc. at an extraordinary general meeting…
TBPHTheravance Biopharma, Inc.
Theravance Biopharma shareholders approved the proposed merger with Zymeworks Inc. at an extraordinary general meeting on September 18, 2026. The Merger Proposal received 40,993,370 votes in favor against 8,671 opposed and 84,733 abstentions, representing approval by more than two-thirds of the voting shares. Shareholders also approved an advisory resolution on merger-related executive compensation with 40,587,829 votes for. The transaction is expected to close around September 23, 2026, subject to other conditions. Theravance Biopharma operates in the biotechnology industry, focusing on drug discovery and development.